Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies
In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China
Paired SARS-CoV-2 spike protein mutations observed during ongoing SARS-CoV-2 viral transfer from humans to minks and Back to humans
A mutation analysis of SARS-CoV-2 genomes collected around the world sorted by sequence, date, geographic location, and species has revealed a large number of variants from the initial reference sequence in Wuhan.
A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques
Our FLOVID-20 team released a new research preprint showing that Rhesus Monkeys vaccinated with FLOVID-20 were free of pneumonia-like infiltrates characteristic of SARS-CoV-2 (COVID-19) infection and presented with lower viral loads relative to controls.
An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design
Development of safe and effective vaccines for some viruses such as HIV and EBOV has been challenging 19.
Anti-IL-6 Versus Anti-IL-6R Blocking Antibodies to Treat Acute Ebola Infection in BALB/c Mice: Potential Implications for Treating Cytokine Release Syndrome
Cytokine release syndrome (CRS) is known to be a factor in morbidity and mortality associated with acute viral infections including those caused by filoviruses and coronaviruses.
An Approach for a Synthetic CTL Vaccine Design Against Zika Flavivirus Using Class I and Class II Epitopes Identified by Computer Modeling
The threat posed by severe congenital abnormalities related to Zika virus (ZKV) infection during pregnancy has turned development of a ZKV vaccine into an emergency.
Eliciting Cytotoxic T-lymphocyte Responses From Synthetic Vectors Containing One or Two Epitopes in a C57BL/6 Mouse Model Using Peptide-containing Biodegradable Microspheres and Adjuvants
To date, an effective vaccine for HIV has yet to be realized